BridgeBio Pharma Enters Material Definitive Agreement

TL;DR

BBIO just signed a big deal, details TBD.

AI Summary

On March 1, 2024, BridgeBio Pharma, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.

Why It Matters

This filing signals a significant development for BridgeBio Pharma, potentially impacting its strategic direction, partnerships, or financial standing.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.

Key Players & Entities

• BridgeBio Pharma, Inc. (company) — Registrant
• March 1, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Palo Alto, CA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
• $310 million — ant, Eidos is entitled to receive up to $310 million in upfront, regulatory, and sales miles

Filing Documents

• ef20022786_8k.htm (8-K) — 31KB
• 0001140361-24-010920.txt ( ) — 164KB
• bbio-20240301.xsd (EX-101.SCH) — 4KB
• bbio-20240301_lab.xml (EX-101.LAB) — 21KB
• bbio-20240301_pre.xml (EX-101.PRE) — 16KB
• ef20022786_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement On March 1, 2024, certain subsidiaries of BridgeBio Pharma, Inc. (the "Company"), including Eidos Therapeutics, Inc. ("Eidos"), BridgeBio International GmbH and BridgeBio Europe B.V., entered into an exclusive license agreement (the "Agreement") with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG ("Bayer"), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the "Licensed Territory"). Under the terms of the Agreement, Eidos granted Bayer an exclusive license, effective upon the date that certain antitrust clearances have been obtained, to certain of Eidos' intellectual property rights to develop, manufacture and commercialize acoramidis (AG10) in the Licensed Territory. In consideration for the license grant, Eidos is entitled to receive up to $310 million in upfront, regulatory, and sales milestone payments through 2026, and is eligible for additional payments subject to the achievement of certain sales milestones. In addition, Eidos is entitled to receive royalties according to a tiered structure starting in the low-thirties percent on net sales by Bayer of acoramidis in the Licensed Territory, subject to reduction under certain circumstances as provided in the Agreement. Unless earlier terminated, the Agreement will expire at the end of the royalty term for a licensed product, provided that the licenses granted to Bayer for such licensed product survive such expiration on a non-exclusive basis. Either party may terminate the Agreement in the event of a material breach or insolvency of the other party or in the event merger control proceedings are started and clearances are not obtained. Additionally, Bayer may terminate the Agreement for convenience upon at least 270 days' prior written notice, and Eidos may terminate the Agreement in the event Bayer ceases exploitation of acora

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: March 4, 2024 By: /s/ Brian C. Stephenson Brian C. Stephenson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR